近日，浙江大学药学院杜永忠教授课题组在纳米医学杂志Nanomedicine-Nanotechnology Biology and Medicine上发表了题为《High tolerated paclitaxel nano-formulation delivered by poly (lactic-co-glycolic acid)-g-dextran micelles to efficient cancer therapy》的研究文章(http://www.sciencedirect.com/science/article/pii/S1549963415000489)。临床编辑做出了Potential clinical relevance的评价。

 Chemotherapy for cancer has always been hampered the toxic side effect of the drugs. Nanotechnology has helped to produce various drug delivery systems to minimize these side effects. In this article, the authors designed dextran-based micelles loaded with paclitaxel. They showed effective anti-tumor activity in both in vitro and in vivo experiments with significant lower systemic toxicity.

       论文研究以右旋糖酐（临床上常用的血浆替代品）为主要材料，辅以简单的药用辅料聚乳酸-羟基乙酸共聚物的结构修饰，构建抗肿瘤化疗药物紫杉醇的靶向递释制剂。体内外的研究结果表明：与市售制剂泰素相比，该制剂体现出等剂量等效的药理作用，并可克服耐药肿瘤的耐药性；然而采用市售制剂最大耐受剂量8倍的给药剂量，小鼠也不会出现死亡；通过提高给药剂量，可实现荷瘤模型动物肿瘤的完全根除。

      课题组目前主要致力于以天然和内源性的物质为材料，开展创新制剂研究，并应用于肿瘤、神经系统疾病和细菌感染等的安全高效治疗。文章的第一作者为2011级硕士生刘萍和2013级硕士生司徒俊青。课题受到浙江省自然科学基金重点项目的资助。